United States vs. European Healthcare – Why Spending More Doesn't Always Mean Better Care
Malgorzata Guyot is a finance and operations executive with over 20 years of global experience helping organizations navigate growth and transformation across Europe and the United States. She holds a PhD from Télécom SudParis, a leading French university.
Two healthcare systems, two different philosophies, and the difficult balance between cost, quality, and access. The United States spends significantly more per person on healthcare than most other developed countries. However, this higher spending does not consistently translate into better health outcomes, whether measured by life expectancy, chronic disease prevalence, or other population health indicators. How is it possible that a country investing so heavily in healthcare does not necessarily achieve better results?
Having worked in the life sciences on both sides of the Atlantic, I have had the opportunity to observe these differences from several perspectives. Recently, I joined Christopher Kunney on the Straight Out of Health IT podcast to discuss the economics of American and European healthcare systems. Our conversation brought us back repeatedly to one fundamental conclusion: there is no perfect healthcare system, and every country makes compromises between cost, quality, and access.
1. Why is American healthcare so expensive?
In most industries, competition is expected to drive prices down. More competitors usually mean greater choice, better efficiency, and lower costs for consumers. Healthcare in the United States, however, seems to challenge this principle, as its highly competitive and largely decentralized structure coexists with some of the highest healthcare costs in the world.
Unlike many European countries, where governments play a central role in financing and negotiating healthcare services, the American system involves numerous private organizations. Insurance companies, hospitals, pharmaceutical companies, pharmacy benefit managers, distributors, and other intermediaries all participate in delivering and financing care. Each performs a function, incurs operating costs, and, in many cases, needs to generate a profit.
As a result, healthcare becomes an extremely complex network of organizations, contracts, negotiations, and financial transactions. This complexity requires administrative staff, technology, compliance processes, and extensive coordination, all of which contribute to the final cost of care.
2. The surprising economics of pharmaceutical innovation
One of the most striking differences between Europe and the United States has historically been the price of prescription medicines. In many European countries, governments negotiate or regulate pharmaceutical prices, often considering therapeutic benefits, existing alternatives, and public healthcare budgets. In the United States, pharmaceutical pricing has traditionally been more driven by market forces, although recent government initiatives, including the Trump administration's efforts to link American drug prices to those paid in other developed countries, signal a shift toward greater pricing intervention.
The result is that the same medicine can cost substantially more in the United States than in Europe. At first glance, the conclusion seems obvious: European countries have found a more effective way to control pharmaceutical costs. However, there is another side to the story that is often overlooked in public discussions about drug prices.
Developing a new medicine is extraordinarily expensive and risky, requiring investments in research, clinical trials, and regulatory approvals, often over many years. Many research projects never result in an approved treatment, meaning that revenues from successful products play an important role in financing future innovation. The United States market has historically generated a disproportionate share of global pharmaceutical revenues and profits, helping companies finance research and development that ultimately benefits patients worldwide. Therefore, any significant change in pharmaceutical pricing must also consider its potential impact on future research, investment, and the development of new treatments.
3. Healthcare as a right or something you buy?
Perhaps the most fundamental difference between European and American healthcare systems is not financial but philosophical. In much of Europe, access to essential healthcare is considered a social right, supported by broad public coverage regardless of individual income. In the United States, healthcare operates within a mixed public and private model, where insurance coverage, employment, and financial resources can significantly influence the cost and accessibility of treatment.
I remember one of my first surprising experiences after moving to the United States, during a casual conversation with a colleague who had given birth to a premature baby. She described an extremely difficult period for her family, and when I asked how long she had stayed in the hospital, she explained that financial considerations had limited their ability to remain there. Coming from Europe, I found it almost unimaginable that the cost of hospitalization could become such an important consideration for parents of a premature baby. In the European systems I knew, the duration of medically necessary hospitalization would normally be determined by physicians rather than the family's financial resources.
Of course, this does not mean that European healthcare is without problems. Universal coverage does not guarantee immediate access to every specialist or treatment, and waiting times can be long, particularly for certain procedures that are not emergencies. In the United States, patients with comprehensive insurance coverage may benefit from excellent medical facilities, advanced technologies, and specialized treatments, sometimes with considerably shorter waiting times.
These differences illustrate the difficult balance between providing broad access to essential healthcare and ensuring timely access to services of the highest quality. European systems generally prioritize universal coverage, even when this creates constraints on resources and waiting times, while the American system offers significant medical capabilities but exposes some patients to substantial financial barriers. Neither approach is entirely satisfactory, and both raise important questions about how societies should allocate limited healthcare resources.
4. The hidden costs we rarely think about
When comparing healthcare costs internationally, we often focus on the most visible differences, such as hospital bills, insurance premiums, prescription drugs, or physician salaries. American doctors generally earn more than their European counterparts, which may suggest that higher compensation contributes to higher healthcare costs. However, looking at salaries alone provides an incomplete picture of the economic environment in which physicians operate.
American physicians may graduate with substantial student debt and face significant malpractice insurance expenses throughout their careers. In many European countries, medical education is heavily subsidized, allowing physicians to begin their professional lives with a very different financial situation. Litigation risk can also influence medical decisions, as physicians may feel pressure to order additional examinations or procedures to reduce potential legal exposure. The cost of healthcare is therefore not simply the cost of medical treatment, but also the cost of the entire system surrounding its delivery.
5. What would the perfect healthcare system look like?
Toward the end of our podcast conversation, Christopher asked me a fascinating question: if I could design a healthcare system from scratch, what would I borrow from Europe and what would I borrow from the United States? My immediate reaction was that I wished the answer were simple, because both models have important strengths and significant limitations. The challenge is not identifying what works well in each system, but understanding whether those advantages can realistically coexist.
From Europe, I would borrow the principle of broad access to essential healthcare, stronger coordination, and greater control over costs. From the United States, I would want to preserve the capacity for medical innovation, investment in new technologies, and the entrepreneurial environment that supports the development of new treatments. Combining these strengths, however, is much more complicated than simply selecting the best features of each model.
Every healthcare system operates with limited resources, even in the wealthiest countries. Increasing access requires funding, improving quality often requires additional investment, and controlling costs may involve difficult decisions about which treatments can be provided, how quickly, and to whom. These three dimensions, cost, quality, and access, are closely connected, and no country has managed to optimize all three perfectly.
Perhaps the most promising common ground lies in prevention. A population's health depends not only on medical treatment but also on lifestyle, nutrition, physical activity, environmental factors, and the prevalence of chronic conditions. Investing more in preventive care, early diagnosis, and healthier lifestyles could improve quality of life while reducing some of the costs associated with preventable diseases over the long term.
What can we learn from each other?
Comparisons between American and European healthcare often turn into debates about which system is better, but after working in both environments, I believe that this is the wrong question. European systems demonstrate that broad healthcare coverage and stronger cost controls are possible, although they come with challenges related to waiting times, funding, and resource allocation. The American system demonstrates the extraordinary potential of private investment and medical innovation, while also revealing the difficulties created by fragmented financing and unequal affordability.
Instead of searching for one perfect model, we should focus on understanding which mechanisms truly improve healthcare outcomes and which create unnecessary costs. Reducing administrative complexity, improving access to essential services, preserving incentives for innovation, and strengthening preventive care are all areas worth exploring.
Ultimately, healthcare is different from most other industries because its purpose goes far beyond delivering a service or generating an economic return. It is about helping people live longer, healthier lives, while ensuring that the resources available to society are used as effectively as possible.
This article was inspired by my recent conversation with Christopher Kunney on the Straight Out of Health IT podcast, where we explored the economic and structural differences between American and European healthcare systems.
Read more from Malgorzata Guyot
Malgorzata Guyot, International Finance Executive
Malgorzata is a finance and operations executive with over 20 years of global experience helping organizations navigate growth and transformation across Europe and the United States. She has worked with both publicly listed and private equity-backed companies, supporting leadership teams through periods of change, expansion, and complexity. Her career has taken her across multiple countries and cultures, shaping a global perspective and a practical, people-centered approach to leadership. Today, she advises executives and boards on building resilient organizations, strengthening governance, and making better strategic decisions. Malgorzata holds a PhD from Télécom SudParis, a leading French university.
